Syndax Pharmaceuticals Inc. ( (SNDX) ) has released its Q3 earnings. Here is a breakdown of the information Syndax Pharmaceuticals Inc.

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

"We expect this transaction to fund us through profitability, while ensuring that we continue to participate in the profits from Niktimvo and retain the upside of its future growth. With this ...

Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode. You'll have an ...

Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. Find out ...

"This has been a historic period for Syndax as we transitioned to a commercial-stage company with the approval of Niktimvo. With the recently completed royalty financing, we expect to be funded ...

The US regulator has cleared the anti-CSF-1R antibody under the Niktimvo brand for the treatment of chronic GvHD after failure of at least two prior lines of systemic therapy in adult and ...

Greetings, and welcome to the Incyte third-quarter financial results conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...